Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia-Reference-Cited by-同舟云学术

Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia

Published:2019-01-01 Issue:1 Volume:26 Page:72-83
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Kameyama Noriko¹,Maruyama Chizuko¹,Kitagawa Fuyuha²,Nishii Kazunobu²,Uenomachi Kaori²,Katayama Yayoi³,Koga Hiromi⁴,Chikamoto Naoko⁴,Kuwata Yuko⁵,Torigoe Junko⁶,Arimoto Masako⁶,Tokumaru Toshiaki⁷,Ikewaki Katsunori⁸,Nohara Atsushi⁹,Otsubo Yoshihiko¹⁰,Yanagi Koji¹¹,Yoshida Masayuki¹²,Harada-Shiba Mariko¹³

Affiliation:

1. Department of Food and Nutrition, Faculty of Human Sciences and Design, Japan Women's University

2. Department of Clinical Nutrition, National Cerebral and Cardiovascular Center

3. Department of Nutrition, Kenporen Osaka Central Hospital

4. Department of Nutritional Management, Shin-Koga Clinic, Medical Group Tenjin-kai

5. Department of Nutrition, Tokorozawa Heart Center

6. Department of Clinical Nutrition, Tokyo Medical and Dental University Medical Hospital

7. Department of Nutrition Management, Kanazawa University Hospital

8. Division of Neurology, Anti-Aging, and Vascular Medicine, Department of Internal Medicine, National Defense Medical College

9. Kanazawa University Health Service Center

10. Department of Internal Medicine, Shin-Koga Clinic, Medical Group Tenjin-kai

11. Department of Cardiovascular Medicine, Kenporen Osaka Central Hospital

12. Life Science and Bioethics Research Center, Tokyo Medical and Dental University

13. Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/26/1/26_44107/_pdf

Reference27 articles.

1. 1) Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjaerg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O and Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia: Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J, 2014; 35: 2146-2157

2. 2) Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR and Tybjaerg-Hansen A; European Atherosclerosis Society Consensus Panel: Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J, 2013; 34: 3478-3490a

3. 3) Makino H and Harada-Shiba M: Long-term effect of low-density lipoprotein apheresis in patients with homozygous familial hypercholesterolemia. Ther Apher Dial, 2003; 7: 397-401

4. 4) Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AME, Propert KJ, Sasiela WJ, Bloedon LT and Rader DJ; Phase 3 HoFH Lomitapide Study investigators: Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet, 2013; 381: 40-46

5. 5) Harada-Shiba M, Ikewaki K, Nohara A, Otsubo Y, Yanagi K, Yoshida M, Chang Q and Foulds P: Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia. J Atheroscler Thromb, 2017; 24: 402-411

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Beneficial Effect of Lomitapide on the Cardiovascular System in LDLr−/− Mice with Obesity;Antioxidants;2023-06-16

2. Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022;Journal of Atherosclerosis and Thrombosis;2023-05-01

3. The microsomal triglyceride transfer protein inhibitor lomitapide improves vascular function in mice with obesity;Obesity;2022-03-06

4. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia;Expert Opinion on Drug Safety;2019-05-04